Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparison of Relapse Risk Prediction Models During Active Surveillance in Stage I Seminoma: A Retrospective Multicenter Cohort Study.

International journal of cancer·2026

Same author

10-Years of First-Line Ipilimumab and Nivolumab in Advanced Melanoma: A Single Centre Experience.

International journal of cancer·2026

Same author

Distinguishing Chronic and Non-Chronic Depression: A Clinical Profile and Symptom Networks Approach.

Psychotherapy and psychosomatics·2026

Same author

Addition of Intravesical Recombinant Bacillus Calmette-Guérin to Perioperative Chemoimmunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/19.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Journal for immunotherapy of cancer·2026

Same author

European Association of Urology Guidelines on Testicular Cancer: Summary of the 2026 Guidelines.

European urology·2026

Search research articles

Related Experiment Video

Updated: May 10, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Case Report: Abiraterone in brain metastases from prostate cancer.

Tobias Peres¹, Stefanie Aeppli¹, Stefanie Fischer¹

¹Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen (KSSG), St. Gallen, Switzerland.

Frontiers in Oncology

|April 28, 2025

Summary

Brain metastases from prostate cancer (PC) are rare. Abiraterone combined with androgen deprivation therapy demonstrated a sustained response in a patient with metastatic hormone-sensitive PC and multiple brain lesions.

Keywords:

abiraterone blood-brain barrier brain metastases case report cerebral metastasis hormonesensitive metastatic prostate cancer

More Related Videos

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

Related Experiment Videos

Last Updated: May 10, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

Area of Science:

Oncology
Neurology
Medical Research

Background:

Prostate carcinoma (PC) is a prevalent cancer in men globally.
Brain metastases (BM) from PC are uncommon, typically occurring late in disease progression.
No standard treatment exists for PC with BM; abiraterone's efficacy is unestablished.

Observation:

An 83-year-old male with metastatic hormone-sensitive PC presented with multiple BM at diagnosis.
Symptoms included dizziness, ataxia, and unsteady gait.
The patient received combination therapy with abiraterone and androgen deprivation therapy.

Findings:

The combination therapy achieved a remarkable and sustained response in cerebral tumors.
After 12 months, the patient became asymptomatic with an excellent performance status.
This case represents a rare instance of symptomatic BM from PC.

Implications:

Abiraterone and androgen deprivation therapy may offer a viable treatment option for symptomatic BM from PC.
This approach shows potential for sustained tumor response and improved patient outcomes.
Further research is warranted to explore this therapeutic strategy in similar cases.